Arvinas, Inc.
ARVN- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001655759
No open-market purchases or sales by Arvinas, Inc. insiders were filed in the last 90 days; 201 institutions reported holding it in 13F filings for Q2 2026, worth $468.7M in total; no superinvestor holds it.
13F holders, Q3 2021
Institutional positions in Arvinas, Inc. as of Sep 30, 2021. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 205
- +26 vs. Q2 2021
- Shares held
- 44.3M
- −1.22M (−2.7%) vs. Q2 2021
- Total value
- $3.64B
- +$135.0M (+3.9%) vs. Q2 2021
- New holders
- 46
- 81 more added
- Sold out
- 20
- 51 more reduced
2 institutions that held it in Q2 2021 haven't filed for Q3 2021 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q2 2021: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting ARVN on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 201 | $468.7M |
| Q1 2026 | 207 | $572.6M |
| Q4 2025 | 206 | $662.9M |
| Q3 2025 | 211 | $570.7M |
| Q2 2025 | 215 | $513.8M |
| Q1 2025 | 216 | $456.7M |
| Q4 2024 | 199 | $1.47B |
| Q3 2024 | 206 | $1.78B |
| Q2 2024 | 207 | $1.89B |
| Q1 2024 | 223 | $2.84B |
| Q4 2023 | 213 | $2.67B |
| Q3 2023 | 155 | $959.0M |
| Q2 2023 | 156 | $1.16B |
| Q1 2023 | 171 | $1.34B |
| Q4 2022 | 162 | $1.71B |
| Q3 2022 | 174 | $2.22B |
| Q2 2022 | 172 | $2.08B |
| Q1 2022 | 179 | $3.16B |
| Q4 2021 | 199 | $3.69B |
| Q3 2021 | 205 | $3.64B |
| Q2 2021 | 181 | $3.52B |
| Q1 2021 | 181 | $2.88B |
Institutions, Q3 2021
Shares, value and share of portfolio for each institution holding Arvinas, Inc.; share changes are against Q2 2021.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Price T Rowe Associates Inc | 2,557,154 | $210.1M | 0.02% | +77,385+3.1% | Added |
| BlackRock Inc. | 3,275,456 | $269.2M | 0.01% | +165,086+5.3% | Added |
| Vanguard Group Inc | 3,800,932 | $312.4M | 0.01% | +129,320+3.5% | Added |
| FMR LLC | 7,053,306 | $579.6M | 0.05% | +1,070,421+17.9% | Added |
| IFP Advisors, Inc | 1 | – | – | 00.0% | Unchanged |
| Marshall Wace, LLP | 0 | $0 | 0.00% | −511,147−100.0% | Sold out |
| Marshall Wace North America L.P. | 0 | $0 | 0.00% | −449,285−100.0% | Sold out |
| EcoR1 Capital, LLC | 0 | $0 | 0.00% | −321,724−100.0% | Sold out |
| FIL Ltd | 0 | $0 | 0.00% | −86,418−100.0% | Sold out |
| Pura Vida Investments, LLC | 0 | $0 | 0.00% | −31,543−100.0% | Sold out |
| Twinbeech Capital LP | 0 | $0 | 0.00% | −11,631−100.0% | Sold out |
| ETF Managers Group, LLC | 0 | $0 | 0.00% | −8,403−100.0% | Sold out |
| Hudson Bay Capital Management LP | 0 | $0 | 0.00% | −4,066−100.0% | Sold out |
| Verition Fund Management LLC | 0 | $0 | 0.00% | −3,634−100.0% | Sold out |
| Bailard, Inc. | 0 | $0 | 0.00% | −3,300−100.0% | Sold out |
| Quantitative Systematic Strategies LLC | 0 | $0 | 0.00% | −3,196−100.0% | Sold out |
| Blueshift Asset Management, LLC | 0 | $0 | 0.00% | −3,179−100.0% | Sold out |
| Inscription Capital, LLC | 0 | $0 | 0.00% | −3,065−100.0% | Sold out |
| Boothbay Fund Management, LLC | 0 | $0 | 0.00% | −3,046−100.0% | Sold out |
| Credit Agricole S A | 0 | $0 | 0.00% | −2,900−100.0% | Sold out |
| Cambridge Investment Research Advisors, Inc. | 0 | $0 | 0.00% | −2,888−100.0% | Sold out |
| Healthcare of Ontario Pension Plan Trust Fund | 0 | $0 | 0.00% | −2,300−100.0% | Sold out |
| Meeder Asset Management Inc | 0 | $0 | 0.00% | −2,088−100.0% | Sold out |
| FORA Capital, LLC | 0 | $0 | 0.00% | −1,081−100.0% | Sold out |
| Walleye Trading LLC | 0 | $0 | 0.00% | −52−100.0% | Sold out |
| Pictet Asset Management Ltd | – | – | – | – | Not filed |
| CWM, LLC | – | – | – | – | Not filed |